A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma
This Phase 2b study aims to evaluate the efficacy and safety of adavosertib, an inhibitor of the tyrosine kinase WEE1, in subjects with recurrent or persistent uterine serous carcinoma (USC) who have previously received at least 1 prior platinum-based chemotherapy regimen for the management of USC.
Indication: Uterine Serous Carcinoma
Modality: small molecule
Target: Adavosertib
Sponsor: AstraZeneca
Source URL: ClinicalTrials.gov
Source updated: Aug 14, 2023
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Adavosertib
View original source fields
Condition raw: Uterine Serous Carcinoma
Condition normalized: Uterine Serous Carcinoma
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Adavosertib
Target normalized: Adavosertib